Therapeutic Anticoagulation and Critical Care Management of Cortical Venous Thrombosis in Pregnancy

Anticoagulation Strategy

Initiate therapeutic‑dose low‑molecular‑weight heparin (LMWH) immediately after confirming cortical venous thrombosis and continue it throughout pregnancy, for at least 6 weeks postpartum, with a minimum total treatment duration of 3 months from diagnosis. 1
Preferred LMWH regimen is enoxaparin 1 mg/kg subcutaneously twice daily; an alternative is enoxaparin 1.5 mg/kg once daily. 1
LMWH is preferred over unfractionated heparin (UFH) because it provides more predictable therapeutic levels, superior efficacy, a lower risk of heparin‑induced thrombocytopenia, and reduced osteoporosis risk. 1
UFH with aPTT monitoring should be reserved for patients with severe renal impairment (eGFR < 30 mL/min). 2
Routine anti‑factor Xa level monitoring is not required unless there are specific concerns (e.g., extreme body weight or uncertain therapeutic effect). 1

Vitamin K antagonists (warfarin) must not be used because of embryopathy risk and potential fetal bleeding. 2
Direct oral anticoagulants (dabigatran, apixaban, edoxaban, rivaroxaban) are contraindicated due to placental transfer and insufficient safety data. 2
Fondaparinux should be avoided; it crosses the placenta and lacks adequate safety evidence in pregnancy. 3

Admit to the ICU for any hemodynamic instability or altered mental status. 4
Advanced gestational age with concerns about fetal viability mandates continuous fetal monitoring in the ICU. 4

Therapeutic‑dose LMWH must be maintained throughout the entire pregnancy and for at least 6 weeks after delivery, ensuring a minimum of 3 months of treatment from the time of diagnosis. 1

Schedule delivery after discontinuing LMWH 24 hours before the anticipated birth to minimize intra‑partum bleeding. 4
Resume anticoagulation 8–12 hours after vaginal delivery or 12–24 hours after cesarean section, provided bleeding is controlled. 1
Anesthesia consultation is required for neuraxial anesthesia decisions; LMWH must be stopped at least 24 hours prior to epidural or spinal placement. 4

Do not postpone therapeutic anticoagulation while awaiting additional imaging or specialist consultation; treatment delays increase mortality and morbidity. 1
Prophylactic‑dose anticoagulation is insufficient for acute cortical venous thrombosis; therapeutic dosing is mandatory. 1

Enoxaparin administered at 1.5 mg/kg subcutaneously once daily is an acceptable therapeutic regimen for acute cortical venous thrombosis in pregnant patients. 5
Low‑molecular‑weight heparin (LMWH) is strongly preferred over unfractionated heparin (UFH) because it provides more predictable therapeutic levels, superior efficacy, a lower risk of heparin‑induced thrombocytopenia, and reduced osteoporosis risk. 5

Routine anti‑factor Xa level monitoring is not required for LMWH therapy in pregnancy unless there are special circumstances such as extreme body weight, uncertain therapeutic effect, or renal impairment. 5
Anti‑Xa monitoring should be avoided as a routine practice to guide LMWH dosing. 5

Therapeutic‑dose LMWH must be continued for at least 6 weeks postpartum to cover the period of persistent pregnancy‑associated hypercoagulability. 5
LMWH should be discontinued 24 hours before a scheduled delivery (induction or cesarean) to reduce intrapartum bleeding risk. Coordination with obstetrics is required. 5

LMWH, UFH, and warfarin are considered safe for use during breastfeeding and do not require cessation of nursing. [5][6]
This safety profile permits uninterrupted therapeutic anticoagulation throughout the postpartum period while the mother continues to breastfeed. 5

Pregnancy‑associated venous thromboembolism, including cortical venous thrombosis, is a leading cause of maternal morbidity and mortality in developed countries. [5][7]
The absolute risk of VTE increases 6‑ to 10‑fold during pregnancy compared with age‑matched non‑pregnant women, and many maternal deaths are preventable with optimal anticoagulation. [5][7]